Adverse reactions to antipsychotics in parkinson disease: An analysis of the Spanish Pharmacovigilance database

Clinical Neuropharmacology

Volumn 38, Issue 3, 2015, Pages 69-84

  Lertxundi, Unax ^a   Ruiz, Arantxazu Isla ^b,c   Aspiazu, María Ángeles Solinís ^b,c   Domingo Echaburu, Saioa ^d   García, Montserrat ^e   Aguirre, Carmelo ^e   García Moncó, Juan Carlos ^e  

^a Araba's Mental Health Network   (Spain)

^b Faculty of Pharmacy   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d Alto Deba Integrated Health Organization   (Spain)

^e HOSPITAL DE GALDAKAO   (Spain)

Author keywords

adverse drug reactions; antipsychotics; Parkinson disease; pharmacovigilance

Indexed keywords

ALANINE AMINOTRANSFERASE; AMITRIPTYLINE; ASPARTATE AMINOTRANSFERASE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CEFUROXIME; CLOZAPINE; CREATINE KINASE; DONEPEZIL; ESCITALOPRAM; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE; ROTIGOTINE; SERTRALINE; SULPIRIDE; THIORIDAZINE; TIAPRIDE; TORASEMIDE; TRAMADOL; TRAZODONE; UNINDEXED DRUG; VASOPRESSIN;

ABDOMINAL PAIN; ACUTE PSYCHOSIS; ADULT; AGED; AGITATION; AGRANULOCYTOSIS; AKINESIA; AMNESIA; ARTICLE; ASPIRATION; ASTHENIA; BACKACHE; BEHAVIOR CHANGE; COMA; CONFUSION; CONSTIPATION; CONVULSION; DATA BASE; DEHYDRATION; DELIRIUM; DELUSIONAL DISORDER; DEPRESSION; DIARRHEA; DIPLOPIA; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSARTHRIA; DYSKINESIA; DYSPHONIA; EDEMA; EPIGASTRIC PAIN; EPISTAXIS; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; FATIGUE; FEMALE; FEVER; FRACTURE; GASTROINTESTINAL SYMPTOM; GENITAL EDEMA; GRANULOCYTOPENIA; HALLUCINATION; HEADACHE; HEART PALPITATION; HEPATITIS; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INCREASED APPETITE; INSOMNIA; INTESTINE OBSTRUCTION; LETHARGY; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL SUBJECT HEADINGS; MEDLINE; MIOSIS; MUSCLE RIGIDITY; MYOCLONUS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PARANOIA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RESTLESS LEGS SYNDROME; RESTLESSNESS; SEDATION; SEIZURE; SHIVERING; SIDE EFFECT; SOMNOLENCE; SPAIN; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA; TESTIS DISEASE; THORAX PAIN; THROMBOCYTOPENIA; TREMOR; URINE INCONTINENCE; VERTIGO; VERY ELDERLY; VIVID DREAM; WEIGHT GAIN; XEROSTOMIA; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; META ANALYSIS; PATHOPHYSIOLOGY; PSYCHOLOGY; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PARKINSON DISEASE; PHARMACOVIGILANCE; PSYCHOTIC DISORDERS; QUETIAPINE FUMARATE; SPAIN;

EID: 84930074383     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000080     Document Type: Article

References (120)

1. Weintraub D, Chen P, Ignacio RV, et al. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 2011;68(7):899-904.
2. Friedman JH. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord 2010;16(9):553-560.
3. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010;81(5):617-622.
4. Friedman JH. Parkinson disease psychosis: update. Behav Neurol 2013; 27(4):469-477.
5. Zarowitz BJ. Prevalence of antipsychotic use in long-term care residents with Parkinson dementia. Geriatr Nurs 2012;33(3):217-219.
6. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66(7):996-1002.
7. Capellá D, Laporte JR. La notificación espontánea de reacciones adversas a medicamentos. In: Laporte JR, Tognoni G, eds. Principios de Epidemiología del Medicamento. 2nd ed. Barcelona, Spain: Masson-Salvat, 1993: 147-170.
8. Directive 2001/83/EC. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2009/10/WC500004481.pdf. Accessed October 7, 2014.
9. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525-535.
10. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40(5):832-834.
11. Bonuccelli U, Ceravalo R, Salvetti S, et al. Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration. Neurology 1997;49(6):1587.
12. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. NEngl JMed 1999;340 (10):757-763.
13. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000;12(3):364-369.
14. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55(6):789-794.
15. Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000;55(6):795-799.
16. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17(5): 1031-1035.
17. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52(5):438-445.
18. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75(5):689-695.
19. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27(24):153-156.
20. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20(8):958-963.
21. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007;22(3):313-318.
22. Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68(17):1356-1363.
23. Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009;5:327-332.
24. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results of a double-blind clinical-polysomnography study. Int J Neurosci 2009;119(12):2196.
25. Fernández HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004;27(1):4-5.
26. Schönfeldt-Lecuona C, Connemann BJ. Aripiprazole and Parkinson's disease psychosis. Am J Psychiatry 2004;161(2):373-374.
27. López-Meza E, Ruiz-Chow A, Ramirez-Bermudez J. Aripiprazole in psychosis associated with Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005;17(3):421-422.
28. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21 (12):2078-2081.
29. Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006;21(9): 1538-1539.
30. Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985;235(1):60.
31. Friedman JH, Max J, Swift R. Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa. Clin Neuropharmacol 1987;10(5):470-475.
32. Ostergaard K, Dupont E. Clozapine treatment of drug-induced psychosis in late stages of Parkinson's disease. Acta Neurol Scand 1988; 78(4):349.
33. Roberts HE, Dean RC, Stoudemire A. Clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1989;1(2):190.
34. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989;39(9):1219-1221.
35. Bear D, Lawson W, Burns S, et al. Clozapine in idiopathic Parkinsons. Biol Psychiatry 1989;25:7.
36. Pfeiffer RF, Kang J, Graber B, et al. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990;5(3):239.
37. Bernardi F, Del Zompo M. Clozapine in idiopathic Parkinson's disease. Neurology 1990;40(7):1151-1152.
38. Kahn N, Freeman A, Juncos JL, et al. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991;41(10):1699-1700.
39. Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10(2):216-219.
40. Wolk SI, Douglas CJ. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. J Clin Psychiatry 1992;53(10): 373-376.
41. Lew MF, Waters CH. Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 1993;41(6):669.
42. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7(2):125-131.
43. Gershanik O, Garcia S, Papa S, et al. Analysis of the mechanism of action of clozapine in Parkinson's disease. Mov Disord 1992;7:101.
44. Rosenthal SH, Fenton ML, Harnett DS. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease. Gen Hosp Psychiatry 1992;14(4):285-286.
45. Linazasoro G, Martí Massó JF, Suárez JA. Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord 1993;8(2): 171-174.
46. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993;60:703-706.
47. Pinter MM, Helscher RJ. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993;5(2):135-146.
48. Factor SA, Brown D, Molho ES, et al. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994;44(3 Pt 1): 544-546.
49. Rabey JM, Treves TA, Neufeld MY, et al. Low-dose clozapine in the treatment of levodopa-inducedmental disturbances in Parkinson's disease. Neurology 1995;45(3 Pt 1):432-434.
50. Wagner ML, Defilippi JL, Menza MA, et al. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996;8(3):276-280.
51. Widman LP, Burke WJ, Pfeiffer RF, et al. Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review. J Geriatr Psychiatry Neurol 1997;10(2):63-66.
52. Rudolf J, Grond M, Neveling M, et al. Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. J Neural Transm 1997;104(11-12):1305-1311.
53. Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998;13(3):377.
54. Ruggieri S, De Pandis MF, Bonamartini A, et al. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol 1997;20(3):204-209.
55. Factor SA, Friedman JH, Lannon MC, et al. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16(1): 135-139.
56. Klein C, Gordon J, Pollak L, et al. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003;26(1):8-11.
57. Fernández HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004;19(7):831-833.
58. Fernandez HH, Friedman JH, Lansang MC, et al. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Relat Disord 2004;10(7):439-441.
59. Gomide L, Kummer A, Cardoso F, et al. Use of clozapine in Brazilian patients with Parkinson's disease. Arq Neuropsiquiatr 2008;66(3B): 611-614.
60. Thomas AA, Friedman JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol 2010;33(1):14.
61. Hack N, Fayad SM, Monari EH, et al. An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. PLoS One 2014;19;9 (3):e91545.
62. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986;73(3):295.
63. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990;5(3):225.
64. Jansen EN. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994;89(4):262-265.
65. Ryken TC, Merrell AN. Haloperidol-induced neuroleptic malignant syndrome in a 67-year-old woman with parkinsonism. West J Med 1989; 151(3):326-328.
66. Wolters EC, Jansen EN, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47(4):1085-1087.
67. Jiménez-Jiménez FJ, Tallón-Barranco A, Ortí-Pareja M, et al. Olanzapine can worsen parkinsonism. Neurology 1998;50(4):1183-1184.
68. Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1998;50(4):1195-1196.
69. Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol 1998;21(5): 285-288.
70. Weiner WJ, Minagar A, Shulman LM. Olanzapine for the treatment of hallucinations/delusions in Parkinson's disease (abstract). Mov Disord 1998;13(Suppl 2):62.
71. Stover NP, Juncos JL. Olanzapine treatment of parkinsonian patients with psychosis (abstract). Neurology 1999;52(Suppl 2):A215.
72. Graham JM, Sussman JD, Ford KS, et al. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998;65(5):774-777.
73. Aarsland D, Larsen JP, Lim NG, et al. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999;11(3):392-394.
74. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999;14(6):1014-1016.
75. Marsh L, Lyketsos C, Reich SG. Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics 2001;42(6):477-481.
76. Sa DS, Lang AE. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2001;57(4):747.
77. Evatt ML, Jewart D, Juncos JL. "Seroquel" (ICI 204,636) treatment of psychosis in parkinsonism. Mov Disord 1996;11:595.
78. Juncos JL, Evatt ML, Jewert D. Long term effects of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology 1998;50 (Suppl 4):A70-A71.
79. Parsa MA, Ramirez LF, Loula EC, et al. Effect of clozapine on psychotic depression and parkinsonism. J Clin Psychopharmacol 1991;11(5): 330-331.
80. Samanta J, Stacy M. Quetiapine in the treatment of hallucinations in advanced Parkinson's disease. Mov Disord 1998;13(Suppl 2):S274.
81. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999;14(3):484-487.
82. Dewey RB, O'Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2000;55: 1753-1754.
83. Fernandez HH, Lannon MC, Friedman JH, et al. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15(3):579-581.
84. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000;20(1):54-60.
85. Weiner WJ, Minagar A, Shulman LM. Quetiapine for L-dopa-induced psychosis in PD. Neurology 2000;54(7):1538.
86. Sommer BR. Quetiapine-induced extrapyramidal side effects in patients with Parkinson's disease: case report. J Geriatr Psychiatry Neurol 2001; 14(2):99-100.
87. Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 2003;18:510-514.
88. Reddy S, Factor SA, Molho ES, et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17(4):676-681.
89. Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004;19(1):29-35.
90. Klein C, Prokhorov T, Miniovich A, et al. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol 2006;29(4):215-219.
91. Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in psychotic parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol 2006;253(2): 171-175.
92. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994;344(8923):681.
93. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994;343 (8909):1370.
94. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akynetic-rygid syndromes. J Clin Psychiatry 1995;56(12):556-559.
95. Workman RH Jr, Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997;9(4):594-597.
96. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000;15(6):1230-1237.
97. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000;15(2):301-304.
98. Connemann BJ, Schönfeldt-Lecuona C. Ziprasidone in Parkinson's disease psychosis. Can J Psychiatry 2004;49(1):73.
99. Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Hum Psychopharmacol 2004;19(3):205-207.
100. Gómez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of zyprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005;28(3): 111-114.
101. Michelli F, Taubenslag N, Gatto E, et al. Ziprasidone in psychosis in Parkinson's disease. Clin Neuropharmacol 2005;28(5):254.
102. Oechsner M, Korchounov A. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? Hum Psychopharmacol 2005;20(3):203-205.
103. Berkowitz AL. Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson's disease. Psychiatry (Edgmont) 2006;3 (11):59-63.
104. Shiah IS, Lin CL, Mao WC, et al. Ziprasidone in the treatment of Parkinson's disease psychosis. Eur Psychiatry 2006;21(8):578-579.
105. Schindehütte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007;109 (2):188.
106. Duggal HS, Singh I. Ziprasidone for drug-induced psychotic symptoms in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(2):583-584.
107. Giménez-Roldán S, Mateo D, Navarro E, et al. Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis. Parkinsonism Relat Disord 2001;7(2):121-127.
108. López del Val LJ, Santos S. Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson's disease [in Spanish]. Rev Neurol 2004;39(7):661.
109. Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006;29(6):331-337.
110. Rustembegovic A, Sofic E, Wichart I. Serum prolactin, leptin, lipids and lipoprotein levels during antipsychotic treatment in Parkinson's disease and related psychosis. Med Arh 2006;60(4):211-212.
111. Pintor L, Valldeoriola F, Baillés E, et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson's disease: a randomized open label clinical trial. Clin Neuropharmacol 2012;35(2):61.
112. Lertxundi U, Peral J, Mora O, et al. Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. Am J Health Syst Pharm 2008;65(5):414-419.
113. EMA. Committee for Proprietary Medicinal Products (CPMP) Summary Information on Referral Opinion Following Arbitration Pursuant to Article 30 of Council Directive 2001/83/EC for Leponex and Associated Names, 2002. EMEA/CPMP/6034/02/en/Final. Available at: http://www.ema.europa.eu/ema/. Accessed October 7, 2014.
114. Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psychosis in Parkinson's disease. Ther Adv Neurol Disord 2010;3(6):339-350.
115. Domingo-Echaburu S, Lertxundi U, Gonzalo-Olazabal E, et al. Inappropriate antidopaminergic drug use in Parkinson's disease inpatients. Curr Drug Ther 2012;7:164-169.
116. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003;26(9): 643-659.
117. Lertxundi U, Domingo-Echaburu S, Irigoyen I, et al. Challenges in the pharmacotherapeutic management of the hospitalised patient with Parkinson's disease [in Spanish]. Rev Neurol 2014;58(8):353-364.
118. Hou JG, Wu LJ, Moore S, et al. Assessment of appropriate medication administration for hospitalized patients with Parkinson's disease. Parkinsonism Relat Disord 2012;18(4):377-381.
119. Derry CP, Shah KJ, Caie L, et al. Medication management in people with Parkinson's disease during surgical admissions. Postgrad Med J 2010;86 (1016):334-337.
120. Harrison-Woolrych M, Clark DW. Nose bleeds associated with use of risperidone. BMJ 2004;328(7453):1416.